Quantcast

Latest thyroid cancer Stories

2014-05-17 23:01:16

The Firm is investigating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis and thyroid cancer due to their use of the Type 2 diabetes medication. New York, New York (PRWEB) May 17, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and other product liability claims involving a class of diabetes drugs called incretin mimetics continue to mount in a federal multidistrict litigation now underway in U.S. District Court, Southern District of...

2014-05-14 20:23:42

Data underscore breadth of oncology portfolio WOODCLIFF LAKE, N.J., May 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that 10 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2014. "Anchored by our human health care mission, Eisai's commitment to cancer patients and their families is evidenced by our focus on sometimes overlooked patient...

2014-05-13 08:31:36

SOUTH SAN FRANCISCO, Calif., May 13, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced the launch of its Afirma Malignancy Classifiers to further establish the Afirma Thyroid FNA Analysis as a comprehensive tool for reducing unnecessary surgeries and healthcare costs among the more than 525,000 U.S. patients each year who undergo fine needle aspiration (FNA) biopsies to rule out cancer in thyroid nodules. The Afirma Malignancy Classifiers comprise genomic tests for...

2014-05-06 08:34:15

SOUTH SAN FRANCISCO, Calif., May 6, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that four abstracts supporting the use of the company's Afirma Malignancy Classifiers and enhancing its overall Afirma solution will be presented at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific & Clinical Congress taking place May 14-18, 2014 in Las Vegas. Veracyte developed the Afirma Malignancy Classifiers to further expand the Afirma...

2014-05-02 08:24:46

SOUTH SAN FRANCISCO, Calif. and SAO PAULO, Brazil, May 2, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) and Fleury Medicine and Health today announced a new partnership that will make Veracyte's Afirma Gene Expression Classifier (GEC) available to patients in Brazil, helping to reduce unnecessary surgeries and potentially lower costs there as part of thyroid cancer diagnosis. Financial terms of the agreement were not disclosed. Through the agreement, Fleury, which has...

2014-04-23 20:23:23

WHIPPANY, N.J. and THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 23, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that The Lancet published online results from the Phase 3 DECISION trial which demonstrated that NEXAVAR(®) (sorafenib) tablets significantly extended the time patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is...

2014-04-17 23:01:33

The Firm is actively evaluating Byetta lawsuit claims on behalf of diabetics who allegedly developed pancreatitis, pancreatic cancer or thyroid cancer after taking the incretin mimetic. New York, NY (PRWEB) April 17, 2014 More than 30 federal cases have joined a federal diabetes drug litigation that includes an increasing number of Byetta lawsuit (http://www.byettalawsuit.com/) filings, as well as claims over similarly-designed medications, Bernstein Liebhard LLP reports. Court documents...

2014-04-09 16:23:19

LONDON, April 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Thyroid Cancer Global Clinical Trials Review, H2, 2013Thyroid Cancer Global Clinical Trials Review, H2, 2013SummaryGlobalData's clinical trial report, "Thyroid Cancer Global Clinical Trials Review, H2, 2013" provides data on the Thyroid Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thyroid Cancer. It includes an overview...

2014-03-29 23:01:26

The Firm is investigating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer due to their use of Byetta. New York, New York (PRWEB) March 29, 2014 As Byetta lawsuits (http://www.byettalawsuit.com) continue to move forward in federal court, Bernstein Liebhard LLP notes that a newly published study is raising questions about the costs and benefits associated with newer medications used in the treatment of Type 2 diabetes....

2014-03-01 23:01:16

The Firm is actively investigating Byetta lawsuit claims on behalf of diabetics who may have been diagnosed with pancreatitis, pancreatic cancer or thyroid cancer after taking the medication. New York, New York (PRWEB) March 01, 2014 The federal litigation of Byetta lawsuits (http://www.byettalawsuit.com/) and other claims involving similar Type 2 diabetes drugs has grown to include more than 300 cases, Bernstein Liebhard LLP reports. According to a Case List updated February 19th by the...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related